AGTX Stock Price, Chart, Stats & News

Agentix Corp., a company in the clinical development phase, specializes in the discovery and commercialization of therapeutic agents aimed at treating metabolic disorders. Its pipeline includes two primary candidates: AGTX-2004, a peripherally-acting CB1 receptor antagonist, which has exhibited effectiveness in animal studies for both obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, also demonstrating positive results in animal models for obesity and non-alcoholic fatty liver diseases. The company was founded in 2013, initially known as FairWind Energy, Inc., before officially changing its name to Agentix Corp. in June 2019.